These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 5228101

  • 1. Treatment of myeloproliferative diseases.
    Sellei C.
    Ther Hung; 1966; 14(4):135-6. PubMed ID: 5228101
    [No Abstract] [Full Text] [Related]

  • 2. Busulphan and the lungs. Absence of lung function disturbance in patients treated with busulphan.
    Comhaire F, Van Hove W, Van Ganse W, Van der Straeten M.
    Scand J Respir Dis; 1972; 53(5):265-73. PubMed ID: 4508954
    [No Abstract] [Full Text] [Related]

  • 3. [Cytostatic therapy of chronic myelosis and polycythemia vera with myelobromol (dibrommannitol)].
    Helbig W, Schwenke H, Müldner J.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1969; 92(2):182-96. PubMed ID: 4189864
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Chronic myeloproliferative diseases].
    Sréter L.
    Orv Hetil; 1998 Jul 26; 139(30):1779-83. PubMed ID: 9718944
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May 26; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chemotherapy in polycythemia vera.
    Stecher G, Reinhardt G.
    Acta Genet Med Gemellol (Roma); 1968 Jan 26; 17(1):292-302. PubMed ID: 5241850
    [No Abstract] [Full Text] [Related]

  • 15. Platelet defects in the myeloproliferative disorders.
    Inceman S, Tangün Y.
    Ann N Y Acad Sci; 1972 Oct 27; 201():251-61. PubMed ID: 4509685
    [No Abstract] [Full Text] [Related]

  • 16. [On the effect of a new cytostatic drug in chronic myeloses and polycythemias].
    Böhnel J, Stacher A.
    Wien Med Wochenschr; 1968 Sep 14; 118(37):721-3. PubMed ID: 5248360
    [No Abstract] [Full Text] [Related]

  • 17. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May 14; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Rukavitsyn OA, Pop VP, Seriakov AP.
    Vopr Onkol; 2004 May 14; 50(4):435-9. PubMed ID: 15605767
    [Abstract] [Full Text] [Related]

  • 20. The management of elderly patients with myeloproliferative disorders.
    Tura S.
    Hematol Oncol; 1993 May 14; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.